Madrigal Pharmaceuticals (MDGL) announced that Bill Sibold has succeeded Paul Friedman, M.D., as Chief Executive Officer, CEO, and joined Madrigal’s Board of Directors. Dr. Friedman, who has served as Madrigal’s CEO since 2016, will continue to serve on the Board of Directors. From 2017 until joining Madrigal, Sibold served as Executive Vice President, Specialty Care of Sanofi (SNY) and President, Sanofi North America.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDGL:
- Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer
- Paulson buys Madrigal, exits Bally’s in Q2
- Biotech Alert: Searches spiking for these stocks today
- Madrigal Pharmaceuticals price target lowered to $285 from $350 at Oppenheimer
- JMP says Madrigal selloff misplaced, ups target to $409